This is the preeminent genome science and technology conference for top global researchers, leaders and innovators.
GENERAL MEETING PREVIOUS SPEAKER
Two decades of breathtaking progress in genomics – but the best is yet to come
GENERAL MEETING PREVIOUS SPEAKER
Towards a Canadian national program for genomic profiling of treatment resistant cancers
GENERAL MEETING PREVIOUS SPEAKER
Characterizing influenza virus diversity within and across infected hosts, and the interactions of microbes in the respiratory tract, to better understand the dynamics of viral transmission
GENERAL MEETING PREVIOUS SPEAKER
How allelic variation and gene expression changes contribute to human traits, including diseases, behaviors and other phenotypes
GENERAL MEETING PREVIOUS SPEAKER
Clinical development of tumor-derived DNA as a biomarker for cancer screening, early detection, monitoring and measurement of early residual disease.
GENERAL MEETING PREVIOUS SPEAKER
Co-Executive Director of the institute for Genomic Medicine at Nationwide Children's Hospital and the Nationwide Foundation: Endowed Chair of Genomic Medicine
SAVE THE DATE
AGBT GM 25: February 23–26, 2025 | AGBT GM 26: February 23–26, 2026
The General Meeting is AGBT’s flagship event for bringing together global leaders, researchers, and innovators.
Advances in Genome Biology and Technology (AGBT) delivers a premier experience where heads of labs, institutions, businesses, financial analysts and other high-level stakeholders come together to advance the field and drive game-changing innovation. Significant scientific advances are announced and showcased, science and industry forge enduring partnerships, and significant investments and notable acquisitions are made.
Learn More about Sponsorship – contact Sarahw@agbt.org.
The meeting format includes daytime plenary sessions that feature invited speakers and abstract-selected talks that highlight cutting-edge research across the broad landscape of genomics. The evening concurrent session includes experimental and computational approaches for effectively utilizing the latest DNA sequencing technologies.
Universities and Governments
CEOS, CMOS, and CSOS
Graphic shows: 2022 In-Person Demographics
2023 FEATURED SPEAKERS
Dame Sue Hill
Researcher at Wellcome Sanger Institute
Alex Cagan investigates evolutionary processes in somatic tissue. His research focuses on characterising mutation and selection in healthy tissues and how this relates to cancer and ageing. Evolution is often considered to be an almost imperceptibly slow process. However, the cells that compose our own bodies are constantly acquiring mutations. Some of these mutations may influence cellular phenotypes, such as growth, resulting in clonal expansions. Over time the body may become a patchwork of clones.
Research associate at the Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
Solenne is a molecular biologist and bioinformatician passionate about the complexity of human and non-human genomes, interested in using genomic to help navigate some of today’s worldwide challenges, such as ensuring equal access to personalized medicine to everyone around the globe, regardless of their origin or economic background, and studying climate change repercussions on earth biodiversity and fresh water / food supply to help prevent future dramatic events.
Professor at Centre for Palaeogenetics, Stockholm, University
Love Dalen’s general research interests are focused on the use of DNA technology to investigate the ecology and evolution of different species, and how past environmental changes have determined the distribution and abundance of organisms.
Chief Scientific Officer at NHS England
Professor Dame Sue Hill OBE PhD DSC CBiol FRSB Hon FRCP Hon FRCPath is the Chief Scientific Officer for England – providing expert clinical scientific advice across the health system and head of profession for the healthcare science workforce in the NHS and associated bodies – embracing more than 50 separate scientific specialisms.
Population Biologist at The University of Sydney
Carolyn has been working on the conservation of threatened species for over twenty-five years both in Australia and overseas. She is currently the Senior Research Manager for the Australasian Wildlife Genomics Group in the Faculty of Science. She has been working with the Save the Tasmanian Devil Program for the past ten years; in addition to other species such as orange-bellied parrots, koalas, bilbies, and woylies.
Working closely with both her academic and conservation management partners her vision is to create a conservation legacy for Australia by changing the way we integrate science, management, and policy; to proactively promote species’ resilience in the face of a changing world. We are achieving this by developing better tools and technologies to integrate molecular genetics into real-time conservation management decisions.
Chief Science Officer at Centers for Disease Control and Prevention/ Office of Advanced Molecular Detection
Duncan MacCannell is the chief science officer for the CDC’s Office of Advanced Molecular Detection (OAMD), where he helps coordinate the implementation and support of pathogen genomics, bioinformatics, high-performance computing and other innovative laboratory technologies across the CDC’s four infectious disease centers.
Professor and Lab Director at The University of British Columbia
Judith Mark uses evolutionary, genomic, and population genetic tools to ask fundamental questions related to how selection acts on males and females within a species, and how the genome responds to contradictory selection to encode sexually dimorphic traits.
Assistant Investigator at Analytic and Translational Genetics Unit at Mass General Research Institute and Harvard Medical School
Alicia R. Martin, Ph.D., is an Instructor in Investigation at the Analytic & Translational Genetics Unit at Massachusetts General Hospital, an Instructor in Medicine at Harvard Medical School, and an Associated Scientist at the Broad Institute affiliated with the Stanley Center for Psychiatric Research and the Medical and Population Genetics Program. As a population and statistical geneticist, her research examines the role of human history in shaping global genetic and phenotypic diversity.
Assistant Professor at UC Santa Cruz
Karen Miga, assistant professor of biomolecular engineering at UC Santa Cruz, was named one of the 100 most influential people of 2022 by TIME. The honor was announced on May 23.
Miga and her colleagues, Adam Phillippy, Evan Eichler, and Michael Schatz, led an international team of scientists — the Telomere-to-Telomere (T2T) Consortium — to complete the first, gapless sequence of the human genome. Parts of the human genome are now available to study for the first time, allowing researchers to better understand genetic diseases, human diversity, and evolution.
Deputy Director and Professor at The University of British Columbia
Dr. Miller joins UBC from the Hospital for Sick Children in Toronto, where she was a Senior Scientist and Professor at the University of Toronto. She is a Fellow of the Royal Society of Canada and of the American Association for the Advancement of Science and at the Hospital for Sick Children she was a Howard Hughes Medical Institute International Research Scholar and the Canada Research Chair in Developmental Neurobiology. Most recently, Dr. Miller’s accomplishments were recognized by the naming of the “Dr. Freda Miller” public school by the Calgary Board of Education.
Associate Professor at University of California, Santa Cruz
Dr. Benedict Paten is an associate professor in the Department of Biomolecular Engineering at the University of California Santa Cruz (UCSC) and an associate director of the UC Santa Cruz Genomics Institute. He oversees the Computational Genomics Lab and Computational Genomics Platform groups at UCSC, which together are broadly focused on computational genomics, creating algorithms, software, and services addressing biomolecular challenges.
Professor at Broad Institute of MIT and Harvard
Dr. Sabeti’s lab focuses on developing new analytical and genomic methods to study evolutionary adaptation and genetic diversity in humans and pathogens, with three current research foci: (1) Identifying and characterizing the underlying adaptive changes that have shaped the human species over time; and (2) Investigating genetic diversity in pathogens such as Lassa virus, Ebola virus, Zika virus, and Babesia microti, towards improved diagnostics, surveillance, and interventions, and (3) Developing novels tools to detect and diagnose microbes causing human morbidity and mortality.
Professor at University of California, Santa Cruz
Beth Shapiro is an evolutionary biologist who specializes in the genetics of ice age animals and plants. As Professor of Ecology and Evolutionary Biology at UC Santa Cruz and HHMI Investigator, Beth uses DNA recovered from bones and other remains to study how species evolved through time and how human activities affected this dynamic process. Her PhD research developed tools to infer changes in species’ abundance and distribution from chronological samples of genetic data.
Associate Professor of Biomedical Engineering at Johns Hoplins University
Winston Timp, an associate professor of biomedical engineering, focuses on the development and application of sequencing technologies to gain a deeper understanding of biology and a more accurate set of clinical tools for human disease. He holds joint appointments in the Department of Molecular Biology and Genetics and the Division of Infectious Diseases at the Johns Hopkins University School of Medicine.
Elinor Karlsson, PhD, is associate professor in Bioinformatics and Integrative Biology at the UMass Chan Medical School, and director of Vertebrate Genomics at the Broad Institute of MIT and Harvard. […]
As an Associate Professor at Baylor College of Medicine, Dr. Bonnen is applying her acumen in bioinformatics and human genetics to gene discovery studies for an array of phenotypes and […]
Dr. Kimberly Doheny is an Associate Professor of Genetic Medicine and Pathology at the Johns Hopkins University School of Medicine. She is Director of the Center for Inherited Disease Research, […]
Institute Scientist and Senior Director of the Genomics Platform, Broad Institute of MIT and Harvard Stacey Gabriel is Senior Director of the Genomics Platform at Broad Institute, and has led […]
Eric D. Green
Dr. Eric Green is the Director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH). He is the third NHGRI Director, having been […]
Dr. Hirst is a Senior Scientist and Head of Epigenomics at Canada’s Michael Smith Genome Sciences Centre at BC Cancer, Associate Professor in the Department of Microbiology and Immunology and Associate […]
Christopher E. Mason
Dr. Christopher Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He is also co-Founder and […]
John D. McPherson
Dr. McPherson is the Deputy Director of the UCD Comprehensive Cancer Center and Professor, Department of Biochemistry and Molecular Medicine. He has deep expertise in DNA sequencing and cancer genomics […]
Stephen B. Montgomery
Stephen Montgomery’s laboratory at Stanford University studies genetic effects on gene regulation and gene expression to identify the molecular and cellular mechanisms which define human traits. They focus on understanding […]
Federica Di Palma
Federica Di Palma, is a Professor at the University of East Anglia in the United Kingdom and the Founder and Director of Science is Global strategy and consulting. She is […]
Dr. Len Pennacchio is a Senior Scientist at the Lawrence Berkeley Laboratory (LBL), Deputy Director of the DOE Joint Genome Institute, and Adjunct Professor at the University of California Berkeley. […]
Beth Shapiro is an evolutionary biologist who specializes in the genetics of ice age animals and plants. As Professor of Ecology and Evolutionary Biology at UC Santa Cruz and HHMI […]
Dr. Michael Zody is a computational biologist with over 15 years of experience writing bioinformatic software, analyzing genomic and transcriptomic sequence data, and managing engineers and researchers. He serves as […]
Elinor Karlsson, PhD, is associate professor in Bioinformatics and Integrative Biology at the UMass Chan Medical School, and director of Vertebrate Genomics at the Broad Institute of MIT and Harvard. Her research combines new technology, community science and genomics to investigate diseases and discover the origins of exceptional mammalian traits. Dr. Karlsson’s research includes the Zoonomia project, an international effort to compare the genomes of over 240 mammals (from the African Yellow-spotted Rock Hyrax to the Woodland Dormouse), to identify segments of DNA that are important for survival and health. Dr. Karlsson has a special interest in dog genetics, and her international Darwin’s Ark project invites all dog owners to enroll their dogs in an open data research project exploring the genetic basis of behavior, as well as diseases such as cancer.
Elinor received her B.A. in biochemistry/cell biology and her B.F.A. (Bachelor of Fine Arts) from Rice University, and earned her Ph.D. in bioinformatics from Boston University. She was a postdoctoral fellow with Pardis Sabeti at Harvard University before starting her research group at UMass Chan in 2014.
As an Associate Professor at Baylor College of Medicine, Dr. Bonnen is applying her acumen in bioinformatics and human genetics to gene discovery studies for an array of phenotypes and diseases including disorders caused by mitochondrial dysfunction and cancer. The Bonnen lab develops and applies methods for analyzing next-generation sequence data and interpretation of human variation. We collaborate closely with clinicians to translate our findings to clinical and diagnostic settings.
Specialties: human genetics, genomics, functional genomics, bioinformatics, population genetics, mitochondrial disease, metabolic disease, cancer, NGS
Dr. Kimberly Doheny is an Associate Professor of Genetic Medicine and Pathology at the Johns Hopkins University School of Medicine. She is Director of the Center for Inherited Disease Research, Co-Director of Johns Hopkins Genomics, Co-Director of the Kennedy Krieger Institute Intellectual Developmental Disabilities Research Center Genomics Core and Director of the Laboratory Genetics and Genomics Fellowship program. She received her PhD in Human Genetics in 1993 from Johns Hopkins University and she is board certified in Clinical Molecular Genetics and Clinical Cytogenetics. Dr. Doheny has co-authored over 120 peer-reviewed publications in the area of complex trait genetics, Mendelian gene discovery, and high-throughput genomics. She is currently the lead Principal Investigator for the CIDR Program trans-NIH contract and Co-PI of the Baylor-Hopkins Clinical Genomics Center for All of Us.
Institute Scientist and Senior Director of the Genomics Platform, Broad Institute of MIT and Harvard
Stacey Gabriel is Senior Director of the Genomics Platform at Broad Institute, and has led platform development, execution and operation since the Institute’s founding. She is also Chair of Professional Scientists and serves on the Institute’s Executive Leadership Team.
Gabriel is widely recognized as a leader in genomics technology and project execution. Her early work provided foundational research for the International HapMap Project. She has led the Broad Institute’s contributions to numerous flagship resource generation projects in human genetics including the HapMap, 1000 Genomes Project, The Cancer Genome Atlas (TCGA); National Heart, Lung and Blood Institute’s Exome Sequencing Project (ESP) and TOPMed program. She is Principal Investigator of the Broad Institute All of Us (AoU) Genomics Center, and serves on the AoU Program Steering Committee.
Dr. Gabriel has directed the Genomics Platform since 2012, and prior to that instantiated the first Broad Institute Platform for Genomic Analysis. Under Gabriel’s guidance, the Genomics Platform operates as one of the largest sequencing centers in the world, and continually explores, validates, optimizes, and implements new technologies, methods, and analysis tools to meet the needs of the Broad community and beyond. Gabriel and the members of her team are committed to pushing the boundaries of the genomic frontier through the application of operational excellence, advanced process design, clinical application, data analysis and technology development capabilities. She has been recognized by Clarivate Analytics as one of the most highly cited in molecular biology and genetics scientists in the world six years in a row.
Dr. Gabriel received her B.S. in molecular biology from Carnegie Mellon University and Ph.D. in human genetics from Case Western Reserve University.
Dr. Eric Green is the Director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH). He is the third NHGRI Director, having been appointed by NIH Director Dr. Francis Collins in 2009.
Dr. Green has been at the Institute for more than 25 years, during which he has had multiple key leadership roles. He served as the Institute’s Scientific Director for 7 years, Chief of the NHGRI Genome Technology Branch for 13 years, and Founding Director of the NIH Intramural Sequencing Center for 12 years.
For just over two decades, Dr. Green directed an independent research program that included integral start-to-finish roles in the Human Genome Project and groundbreaking work on mapping, sequencing, and characterizing mammalian genomes.
Dr. Green earned his M.D. and Ph.D. degrees in 1987 from Washington University in St. Louis; coincidentally, the word “genomics” was coined in that same year.
During his career, Dr. Green has authored and co-authored over 375 scientific publications.
Dr. Hirst is a Senior Scientist and Head of Epigenomics at Canada’s Michael Smith Genome Sciences Centre at BC Cancer, Associate Professor in the Department of Microbiology and Immunology and Associate Director of the Michael Smith Laboratory at the University of British Columbia (UBC).
His research focuses on understanding epigenetic dysfunction in cancer and his laboratory develops experimental and computational tools to characterize normal and transformed cell types down to the single cell level. He applies these tools to explore the epigenomic states of normal and transformed cell types to discover and exploit therapeutic vulnerabilities.
Over the last decade, he has led the development of an internationally recognized epigenomic research program at BC Cancer and UBC. He leads the Centre of Epigenomic Mapping Technologies (CEMT) that represents one of two Canadian epigenomic mapping centres funded as part of the CIHR signature initiative: the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC). Dr. Hirst chairs the Scientific Steering Committee of the International Human Epigenome Consortium (ihec.org) and leads the Canadian Epigenetics, Environment and Health Research Consortium Network (epigenomes.ca) with a mandate to drive epigenetic research in Canada and internationally. Dr. Hirst received a TFRI New Investigator Award (2015) and UBC Killam Research Prize (2018) and has been cited over 48,000 times (Clarivate, 2018 Highly Cited Researcher).
Dr. Christopher Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He is also co-Founder and global director at Biotia, co-Founder and scientific director at Onegevity, Director of Genomics at Tempus Labs, and recently published The Next 500 Years: Engineering Life to Reach New Worlds.
Dr. Mason develops and deploys computational and experimental methodologies to identify the functional genetic elements of the human genome and metagenome. To do this, we perform research in three principal areas: (1) molecular profiling in patients with extreme phenotypes, including brain malformations, aggressive cancers, and astronauts, (2) creating new biochemical and computational techniques in DNA/RNA sequencing and DNA/RNA base modifications, and (3) the development of new cell and genome modifications. In the very long term, we believe these systems-based methods will enable an understanding of the functional elements of the human genome and embedded metagenome, such that we can begin to repair or re-engineer these genetic networks for ameliorating disease and lay the foundation to enable long-term human spaceflight.
Dr. Mason has won the NIH’s Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the International Space Station (ISS) Research and Development Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He was named as one of the “Brilliant Ten” Scientists by Popular Science, featured as a TEDMED speaker, and called “The Genius of Genetics” by 92Y. He has written 2 books and >300 peer-reviewed papers, featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by the U.S. District Court and U.S. Supreme Court. Coverage of his work has also appeared on the covers of the Wall Street Journal, New York Times, TIME, The LA Times, and across many media (ABC, NBC, CBS, Fox, CNN, PBS, NASA, NatGeo). He is an inventor on four patents, co-creator of five FDA-authorized diagnostic tests, founded five biotechnology companies, and he serves as an advisor to 21 others, as well as 3 non-profits. He lives with his daughter and wife in Brooklyn, NY.
Dr. Christopher Mason’s background and appointments:
- S. in Genetics, University of Wisconsin-Madison (2001)
- S. in Biochemistry, University of Wisconsin-Madison (2001)
- D. in Genetics, Yale University (2006)
- Post-doc, Clinical Genetics, Yale Medical School (2009)
- Fellowship of Genomics, Ethics, and Law, Yale Law School (2009).
- Assistant Professor, Weill Cornell Medicine (2009)
- Associate Professor, Weill Cornell Medicine (2015)
- Director, the WorldQuant Initiative for Quantitative Prediction (2017),
Appointments at the Tri-Institutional Program on Computational Biology and Medicine between Cornell, Memorial Sloan-Kettering Cancer Center and Rockefeller University, the Sandra and Edward Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute.
Dr. McPherson is the Deputy Director of the UCD Comprehensive Cancer Center and Professor, Department of Biochemistry and Molecular Medicine. He has deep expertise in DNA sequencing and cancer genomics through his involvement in the Human Genome Project and large-scale tumor sequencing as a founding member of the International Cancer Genome Consortium. Within the ICGC, Dr. McPherson led the whole genome sequencing of >200 pancreatic ductal adenocarcinomas using laser capture microdissected material. His current interests lie in bringing advanced genomic technologies to clinical application in personalized diagnosis and targeted therapeutics; in maximizing the data yield from small biopsies and circulating cell free DNA; and in the role of DNA repair in carcinogenesis.
Stephen Montgomery’s laboratory at Stanford University studies genetic effects on gene regulation and gene expression to identify the molecular and cellular mechanisms which define human traits. They focus on understanding the effects of genome variation on cellular phenotypes and cellular modeling of disease through genomic approaches such as next generation RNA sequencing in combination with developing and utilizing state-of-the-art bioinformatics and statistical genetics approaches.
Federica Di Palma, is a Professor at the University of East Anglia in the United Kingdom and the Founder and Director of Science is Global strategy and consulting.
She is passionate about exploring and preserving Biodiversity around the world. She leads a number of multidisciplinary research programmes which use genomics approaches to understand how evolutionary and environmental pressures have shaped the diversity of vertebrate species with implications for food, environment and livelihoods.
She is a visiting scientist at the Earlham Institute, where she was the former Director of Science, and at Broad Institute in Cambridge Ma (US), where she was previously the Assistant Director of the Vertebrate Genome Biology programme.
Dr. Len Pennacchio is a Senior Scientist at the Lawrence Berkeley Laboratory (LBL), Deputy Director of the DOE Joint Genome Institute, and Adjunct Professor at the University of California Berkeley. He received his PhD in Genetics from Stanford University in 1998 under Rick Myers and then served as a DOE Alexander Hollaender Distinguished Fellow at LBL under Eddy Rubin. He has authored over 150 publications and received the Presidential Early Career Award for Scientists and Engineers (PECASE) from the White House for his contributions to the Human Genome Project and understanding mammalian gene regulation in vivo. Dr. Pennacchio has an extensive background in mammalian genetics and genomics as well as with DNA sequencing technologies and their application to address outstanding issues in both the biomedical, energy, and environment sectors. He serves in numerous advisory roles such as NHGRI’s Genome Sequencing Program, the Centre for Genomic Research at the University of Liverpool, as a past permanent member of NIH’s GCAT Study Section. He also is an Organizer and Co-Chair of both annual Advances in Genome Biology & Technology (AGBT) meetings as well as a “Systems Biology of Gene Regulation and Genome Editing” meeting hosted by Cold Spring Harbor Asia. Currently his research is heavily focused on understanding the spectrum of DNA mutations that contribute to human disease through in vivo functional studies.
Beth Shapiro is an evolutionary biologist who specializes in the genetics of ice age animals and plants. As Professor of Ecology and Evolutionary Biology at UC Santa Cruz and HHMI Investigator, Beth uses DNA recovered from bones and other remains to study how species evolved through time and how human activities have affected and continue to affect this dynamic process. Her work focuses on organisms ranging from influenza to mammoths, asking questions about domestication, admixture, speciation, and pathogen evolution. Her current work develops techniques to recover increasingly trace amounts of DNA such as from environmental and forensic samples. A 2009 MacArthur Fellow, Beth is also an award-winning popular science author and communicator who uses her research as a platform to explore the potential of genomic technologies for conservation and medicine.
Beth Shapiro, Professor of Ecology and Evolutionary Biology at UC Santa Cruz and an HHMI Investigator, uses DNA from the past to study how species evolve and how human activities affect this dynamic process. Beth develops tools to recover and analyze genomic data preserved in organismal remains and the environment, asking questions about domestication, admixture, and pathogen evolution. As an author and communicator, Beth uses her research as a platform to explore the potential of genomic technologies for conservation and medicine.
Dr. Michael Zody is a computational biologist with over 15 years of experience writing bioinformatic software, analyzing genomic and transcriptomic sequence data, and managing engineers and researchers. He serves as the Scientific Director of Computational Biology at the New York Genome Center.
He started his career at the Whitehead Institute Center for Genome Research (now part of the Broad Institute) during the pilot-sequencing phase of the Human Genome Project. As Manager of Sequencing Informatics at Whitehead, he led informatics efforts associated with production scaling of human genome sequencing. His group built the first fully-automated barcoding and database tracking system for managing high-throughput sequencing workflows. Dr. Zody also oversaw automated assembly, quality control, and public release of ¼ of the draft sequence of the human genome.
After the initial release of the human genome reference sequence, Dr. Zody co-led mouse genome sequencing efforts and was an analysis group leader for both the mouse and chimpanzee genome analysis consortia. He has worked with nearly every extant commercial sequencing platform and has been part of the early evaluation and adoption teams for several platforms ranging from ABI 3700 capillary sequencers to Solexa (now Illumina) Genome Analyzers. He has published over 50 peer-reviewed articles and written 4 book chapters. Dr. Zody received his PhD in medical science from Uppsala University, Sweden, and earned a SB in materials science and engineering and a SM in metallurgy from MIT.
In addition to his research work, Dr. Zody has served on the organizing committee for the Advances in Genome Biology and Technology (AGBT) meeting since 2007. He travels extensively to teach courses on sequencing technology, analysis, and experimental design. Since 2007, he has been an instructor at the Cold Spring Harbor Advanced Sequencing Technologies and Applications course. He has also taught in such diverse locations as the Smithsonian Institution (2010), Uppsala University (Sweden, 2008-2012), and K-RITH (Durban, South Africa, 2013). Dr. Zody teaches an annual Sequencing Informatics Workshop for the scientific community at the New York Genome Center.